Sign Up for a Free Account
  • Updated 09.05.2021
  • Released 12.22.1998
  • Expires For CME 09.05.2024



Historical note and terminology

Almost 1.5 centuries after the first description of Parkinson disease in 1817, dopamine was shown to be concentrated in the neostriatum of the brains of Parkinson disease patients (05). Dopaminergic deficits in patients with Parkinson disease were described a few years later (03). It was also demonstrated that replenishment of dopamine through intravenous levodopa briefly improved the symptoms of patients with Parkinson disease (06). The success of levodopa started the search for alternative ways to enhance dopaminergic transmission. One of the earlier dopamine agonists to be investigated was apomorphine. It had been used earlier, in 1951, for the treatment of Parkinson disease (34). Ergot derivatives then entered the dopamine agonist arena for the treatment of Parkinson disease. Bromocriptine is the best known example of this class of drugs.

Pramipexole, a non-ergot dopamine agonist, was synthesized in the United States and first manufactured in 1997 under the brand names of Mirapex and Mirapex ER (39). Initial clinical development of pramipexole was as a treatment for schizophrenia and depression, but this use appears to have been discontinued. The first biochemical and pharmacological studies on pramipexole were published in 1992 (27). Pramipexole was first approved in the United States by the Food and Drug Administration in 1997. It was launched for the treatment of Parkinson disease as monotherapy and as an adjunct to levodopa. It has received approval from the European Medicines Evaluation Agency for the same indication. It was also approved for treatment of restless legs.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125